GlassScriptPhysician profile
Mary-Jane Williams
NPI 1285096032
$9,746.55
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $319 · 2020: $23.04 · 2021: $1,448 · 2022: $2,504 · 2023: $3,740 · 2024: $1,713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,206 · Food and Beverage: $1,247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,206.07 |
| Food and Beverage | $1,246.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $4,236.15 | 2023-2024 | Resolution 360 Clip |
| Olympus Corporation of The Americas | $3,164.87 | 2021-2023 | Single Use Electrosurgical Knife Kd-655, Single Use Electrosurgical Hemostatic Forceps |
| Abbvie INC. | $745.84 | 2021-2024 | Rinvoq, Creon |
| Wilson Cook Medical Incorporated | $658.11 | 2021 | |
| Pfizer INC. | $145.00 | 2019 | |
| Cook Medical LLC | $124.87 | 2021 | |
| Janssen Scientific Affairs, LLC | $124.39 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $88.50 | 2020-2022 | |
| Nestle Healthcare Nutrition INC. | $88.42 | 2021-2022 | |
| Regeneron Pharmaceuticals, INC. | $82.72 | 2024 | |
| Intercept Pharmaceuticals, INC. | $75.78 | 2020-2023 | Ocaliva |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.79 | 2022 | |
| Braintree Laboratories, INC. | $31.09 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $26.90 | 2023 | Dupixent |
| Merck Sharp & Dohme LLC | $26.69 | 2019-2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $25.50 | 2022 | |
| Mylan Specialty L.P. | $15.25 | 2019 | |
| Celgene Corporation | $13.02 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.46 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary-Jane Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.